脐血造血干细胞移植的临床研究进展

doi:10.3969/j.issn.1674-490X.2021.03.001

摘要/Abstract

摘要： 脐血已逐渐成为异基因造血干细胞移植治疗中的一个重要的干细胞来源。尽管移植后感染相关病死率稍高, 但由于脐血容易获得、移植后移植物抗宿主病的发生率低等优点,脐血移植患者的存活率与其他类型的造血干细胞移植相当。脐血移植技术的不断改善也给患者带来了较好的疗效,脐血的临床应用为多种难治性疾病的治疗提供了新的方法。现就近年来脐血移植的改进措施、脐血的选择及脐血在其他疾病的应用进行综述。

关键词: 脐血, 干细胞移植, 移植物抗宿主病, 细胞治疗

Abstract: Umbilical cord blood has gradually become an important source of stem cells in allogeneic stem cell transplantation.Although the post-transplantation infective fatality rate is higher, the survival rate of cord blood transplantation is comparable to other types of stem cell transplantation due to the advantages of easy access and lower incidence of GVHD(graft-versus-host diseases, GVHD).The improvement of cord blood transplantation technology has also brought better curative effect to the patients. The clinical application of umbilical cord blood provides a new method for the treatment of many refractory diseases.This article reviews the improvement of cord blood transplantation in recent years, the selection of cord blood for transplantation and the application of umbilical cord blood in other related diseases.

Key words: umbilical cord blood, stem cell transplantation, graft-versus-host diseases, cell therapy

中图分类号:

徐世侠,唐湘凤. 脐血造血干细胞移植的临床研究进展[J]. 医学研究与教育, 2021, 38(3): 1-6.

参考文献

[1] GLUCKMAN E, BROXMEYER H A, AUERBACH A D, et al.Hematopoietic reconstitution in a patient with fanconi's Anemia by means of umbilical-cord blood from an HLA-identical sibling[J].N Engl J Med, 1989, 321(17): 1174-1178.DOI: 10.1056/NEJM198910263211707.
[2] KALYNYCHENKO T O.Umbilical cord blood banking in the worldwide hematopoietic stem cell transplantation system: perspectives for Ukraine[J].Exp Oncol, 2017, 39(3): 164-170.
[3] 北京市脐血库.【脐带血治疗应用】脐带血全球应用超过5万例,中国超过1.2万例[EB/OL].[2020-05-15].https://www.163.com/dy/article/F7GVTPD50538036V.html 2020-03-17.
[4] MATSUMOTO M M, MATTHEWS K R.A need for renewed and cohesive US policy on cord blood banking[J].Stem Cell Rev Rep, 2015, 11(6): 789-797.DOI: 10.1007/s12015-015-9613-9.
[5] DESSELS C, ALESSANDRINI M, PEPPER M S.Factors influencing the umbilical cord blood stem cell industry: an evolving treatment landscape[J].Stem Cells Transl Med, 2018, 7(9): 643-650.DOI: 10.1002/sctm.17-0244.
[6] NAVARRETE C, CONTRERAS M.Cord blood banking: a historical perspective[J].Br J Haematol, 2009, 147(2): 236-245.DOI: 10.1111/j.1365-2141.2009.07827.x.
[7] 喻京英.走进北京脐带血库[N].人民日报海外版, 2009-04-24(14).
[8] EAPEN M, ROCHA V, SANZ G, et al.Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis[J].Lancet Oncol, 2010, 11(7): 653-660.DOI: 10.1016/S1470-2045(10)70127-3.
[9] ROCHA V, KABBARA N, IONESCU I, et al.Pediatric related and unrelated cord blood transplantation for malignant diseases[J].Bone Marrow Transplant, 2009, 44(10): 653-659.DOI: 10.1038/bmt.2009.291.
[10] SMITH A R, WAGNER J E.Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood[J].Br J Haematol, 2009, 147(2): 246-261.DOI: 10.1111/j.1365-2141.2009.07828.x.
[11] WAGNER J E Jr, EAPEN M, CARTER S, et al.One-unit versus two-unit cord-blood transplantation for hematologic cancers[J].N Engl J Med, 2014, 371(18): 1685-1694.DOI: 10.1056/NEJMoa1405584.
[12] WANG L, GU Z Y, LIU S F, et al.Single-versus double-unit umbilical cord blood transplantation for hematologic diseases: a systematic review[J].Transfus Med Rev, 2019, 33(1): 51-60.DOI: 10.1016/j.tmrv.2018.11.001.
[13] BALLIGAND L, GALAMBRUN C, SIRVENT A, et al.Single-unit versus double-unit umbilical cord blood transplantation in children and young adults with residual leukemic disease[J].Biol Blood Marrow Transplant, 2019, 25(4): 734-742.DOI: 10.1016/j.bbmt.2018.10.016.
[14] RAMIREZ P, WAGNER J E, DEFOR T E, et al.Factors predicting single-unit predominance after double umbilical cord blood transplantation[J].Bone Marrow Transplant, 2012, 47(6): 799-803.DOI: 10.1038/bmt.2011.184.
[15] HOUGH R, DANBY R, RUSSELL N, et al.Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols[J].Br J Haematol, 2016, 172(3): 360-370.DOI: 10.1111/bjh.13802.
[16] PIACIBELLO W, SANAVIO F, GARETTO L, et al.Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood[J].Blood, 1997, 89(8): 2644-2653.
[17] HORWITZ M E, WEASE S, BLACKWELL B, et al.Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide[J].J Clin Oncol, 2019, 37(5): 367-374.DOI: 10.1200/JCO.18.00053.
[18] LUND T C, BOITANO A E, DELANEY C S, et al.Advances in umbilical cord blood manipulation- from niche to bedside[J].Nat Rev Clin Oncol, 2015, 12(3): 163-174.DOI: 10.1038/nrclinonc.2014.215.
[19] GUPTA A O, WAGNER J E. Umbilical cord blood transplants: current status and evolving therapies[J]. Front Pediatr, 2020, 8: 570282.DOI: 10.3389/fped.2020.570282.
[20] LIU H T, RICH E S, GODLEY L, et al.Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions[J].Blood, 2011, 118(24): 6438-6445.DOI: 10.1182/blood-2011-08-372508.
[21] BERNARDO M E, BALL L M, COMETA A M,et al.Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation[J].Bone Marrow Transplant, 2011, 46(2): 200-207.DOI: 10.1038/bmt.2010.87.
[22] VAN OS R, AUSEMA A, DONTJE B, et al.Engraftment of syngeneic bone marrow is not more efficient after intrafemoral transplantation than after traditional intravenous administration[J].Exp Hematol, 2010, 38(11): 1115-1123.DOI: 10.1016/j.exphem.2010.07.003.
[23] FRASSONI F, GUALANDI F, PODESTÀ M, et al.Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study[J].Lancet Oncol, 2008, 9(9): 831-839.DOI:10.1016/S1470-2045(08)70180-3.
[24] LUCCHINI G, PERALES M A, VEYS P.Immune reconstitution after cord blood transplantation: peculiarities, clinical implications and management strategies[J].Cytotherapy, 2015, 17(6): 711-722.DOI: 10.1016/j.jcyt.2015.03.614.
[25] HIWARKAR P, HUBANK M, QASIM W, et al.Cord blood transplantation recapitulates fetal ontogeny with a distinct molecular signature that supports CD4⁺ T-cell reconstitution[J].Blood Adv, 2017, 1(24): 2206-2216.DOI: 10.1182/bloodadvances.2017010827.
[26] ADMIRAAL R, CHIESA R, LINDEMANS C A, et al.Leukemia-free survival in myeloid leukemia, but not in lymphoid leukemia, is predicted by early CD4⁺ reconstitution following unrelated cord blood transplantation in children: a multicenter retrospective cohort analysis[J].Bone Marrow Transplant, 2016, 51(10): 1376-1378.DOI: 10.1038/bmt.2016.116.
[27] EAPEN M, WANG T, VEYS P A, et al.Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis[J].Lancet Haematol, 2017, 4(7): e325-e333.DOI: 10.1016/s2352-3026(17)30104-7.
[28] TAKANASHI M, ATSUTA Y, FUJIWARA K, et al.The impact of anti-HLA antibodies on unrelated cord blood transplantations[J].Blood, 2010, 116(15): 2839-2846.DOI: 10.1182/blood-2009-10-249219.
[29] COTTEN C M, MURTHA A P, GOLDBERG R N, et al.Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy[J].J Pediatr, 2014, 164(5): 973-979.e1.DOI: 10.1016/j.jpeds.2013.11.036.
[30] FENG M, LU A L, GAO H X, et al.Safety of allogeneic umbilical cord blood stem cells therapy in patients with severe cerebral palsy: a retrospective study[J].Stem Cells Int, 2015, 2015: 325652.DOI: 10.1155/2015/325652.
[31] NOVAK I, WALKER K, HUNT R W, et al.Concise review: stem cell interventions for people with cerebral palsy: systematic review with meta-analysis[J].Stem Cells Transl Med, 2016, 5(8): 1014-1025.DOI: 10.5966/sctm.2015-0372.
[32] MA J, ZHAO Y Y, SUN L, et al.Exosomes derived from akt -modified human umbilical cord mesenchymal stem cells improve cardiac regeneration and promote angiogenesis via activating platelet-derived growth factor D[J].Stem Cells Transl Med, 2017, 6(1): 51-59.DOI: 10.5966/sctm.2016-0038.
[33] FISHER S A, CUTLER A, DOREE C, et al.Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant(HSCT)recipients with a haematological condition[J].Cochrane Database Syst Rev, 2019, 1(1): CD009768.DOI: 10.1002/14651858.CD009768.pub2.